Clinical value of galectin-9, soluble TREM-1, and soluble CD25 among critically ill patients with organ failure in the emergency department: a prospective observational study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

This study investigated clinical value of galectin-9 (Gal-9), a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and soluble CD25 (sCD25) among critically ill patients with organ failure in the emergency department. Overall, 786 patients were enrolled and classified into: non-infectious organ failure (NIOF, n = 331), sepsis (n = 266), and septic shock (n = 189). The diagnostic value of Gal-9, sTREM-1, and sCD25 were evaluated by receiver operating characteristic curve analysis. The prognostic value of the biomarkers was evaluated using Kaplan–Meier survival curve and Cox proportional hazard model analyses. Gal-9, sTREM-1, and sCD25 could discriminate sepsis from NIOF (Gal-9, area under the curve [AUC], 0.599–0.678; sTREM-1, AUC, 0.616–0.695; sCD25, AUC, 0.710–0.781) and septic shock from sepsis (Gal-9, AUC, 0.562–0.667; sTREM-1, AUC, 0.572–0.676; sCD25, AUC, 0.555–0.660), respectively. Sepsis patients with higher levels of biomarkers over their cut-off value showed higher 30-day mortality compared to those with lower levels below the cut-off value (Gal-9 ≥ 14391.80 ng/L, p  < 0.001; sTREM-1 ≥ 580.62 ng/L, p  < 0.001; sCD25 ≥ 1639.29 ng/L, p  < 0.001; respectively) (log-rank test). sCD25 is an independent risk factor for 30-day mortality in patients with sepsis or septic shock. Gal-9, sTREM-1, and sCD25 showed diagnostic and prognostic value in critically ill patients with organ failure. sCD25 can predict the 30-day mortality in patients with sepsis. Gal-9, sTREM-1, and sCD25 could serve as auxiliary biomarkers to support clinicians in effective sepsis management.

Article activity feed